Momelotinib Effectiveness in Myelofibrosis

Momelotinib During and After HCT in Myelofibrosis

NCT07104799 ·Status: RECRUITING ·Phase: PHASE1

Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

NCT06516406 ·Status: RECRUITING

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

NCT02953704 ·Status: COMPLETED

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

NCT01773187 ·Status: TERMINATED ·Phase: PHASE3

Managed Access Program for Momelotinib in Myelofibrosis

NCT05582083 ·Status: NO_LONGER_AVAILABLE

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT00935987 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

NCT01692366 ·Status: COMPLETED ·Phase: PHASE2

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT01236638 ·Status: COMPLETED ·Phase: PHASE2

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.

NCT01493414 ·Status: COMPLETED ·Phase: PHASE3

A Phase 2 Study With IPI-926 in Patients With Myelofibrosis

NCT01371617 ·Status: COMPLETED ·Phase: PHASE2

A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

NCT05447260 ·Status: UNKNOWN ·Phase: PHASE4

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

NCT01340651 ·Status: COMPLETED ·Phase: PHASE2

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

NCT00724334 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

NCT00303472 ·Status: COMPLETED ·Phase: PHASE2

Ruxolitinib in Patients With Myelofibrosis

NCT05762874 ·Status: UNKNOWN

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

NCT01420770 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis

NCT06909136 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

NCT01437787 ·Status: COMPLETED ·Phase: PHASE3

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

NCT04176198 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study of SB939 in Subjects With Myelofibrosis

NCT01200498 ·Status: COMPLETED ·Phase: PHASE2

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

NCT05714072 ·Status: RECRUITING ·Phase: PHASE1

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

NCT01433445 ·Status: COMPLETED ·Phase: PHASE1

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

NCT04854096 ·Status: TERMINATED ·Phase: PHASE2

Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy

NCT03959371 ·Status: UNKNOWN